REGENERON
SCIENCE TO MEDICINE®

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved or authorized treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary *VelociSuite®* technologies, such as *VelocImmune®*, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about Regeneron, please visit www.regeneron.com or follow Regeneron on LinkedIn.

General Company Information

– Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
– More than 13,000 employees in the U.S., Canada, UK, EU and Asia
– 2022 R&D investment of $3.59 billion

Locations

– Tarrytown, NY: Corporate and Research & Development headquarters
– Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
– Sleepy Hollow, NY, Basking Ridge, NJ, and Washington, D.C.: offices
– Amsterdam, Basel, Bengaluru, Dublin, London, Madrid, Milan, Munich, Paris, Toronto, and Tokyo: Global business offices

Leadership Team

– **Leonard S. Schleifer, MD, PhD**
  Board Co-Chair, Co-Founder, President and Chief Executive Officer
  + *Fellow, American Association for the Advancement of Science (AAAS)*

– **George D. Yancopoulos, MD, PhD**
  Board Co-Chair, Co-Founder, President and Chief Scientific Officer
  + *Member, National Academy of Sciences*

– **Christine A. Poon**
  Lead Independent Director
  Former Vice Chair, Worldwide Chair of Pharmaceuticals, Member of the Executive Committee and Director at Johnson & Johnson

– **Board of Directors** includes two Nobel Laureates and six members of the National Academy of Sciences

FDA-Approved & Marketed Medicines*

EYLEA HD (aflibercept) Injection 8 mg ③

EYLEA® (aflibercept) Injection ③

DUPIXENT® *(dupilumab)* Injection 100mg • 200mg • 300mg ①

Evkeeza® (evinacumab-dgnb) Injection ⑥

Arcalyst® (rilonacept) Injection for Subcutaneous Use ⑤

Inmazeb® (atoltivimab, maftivimab, and odesivimab – ebgn) Injection 16.67 mg / 16.67 mg / 16.67 mg per mL

KEVZARA® (sarilumab) injection 150 mg | 200 mg ①
Please see full Prescribing Information including Boxed WARNING for KEVZARA.

LIBTAYO® (cemiplimab-rwlc) Injection 350 mg

Praluent® (alirocumab) Injection ②

Veopoz™ (pozelimab-bbfg) Injection ⑥
Please see full Prescribing Information including Boxed WARNING for Veopoz.

ZALTRAP® (ziv-aflibercept) ④

① Dupixent and Kevzara are co-developed and co-commercialized by Regeneron and Sanofi. | ② Praluent is marketed by Sanofi outside of the U.S. | ③ EYLEA is marketed by Bayer outside of the U.S. | ④ Zaltrap was jointly developed by Regeneron and Sanofi and is marketed by Sanofi. | ⑤ Arcalyst was developed by Regeneron and is marketed by Kiniksa Pharmaceuticals. | ⑥ Evkeeza is marketed by Ultragenyx outside of the U.S.

* U.S. Food and Drug Administration

US.REGN.23.09.0001

Clinical Product Candidates

PHASE 1

ALN-APP [4]
RNAi therapeutic targeting APP
Early-onset Alzheimer's disease

ALN-HSD
RNAi therapeutic targeting HSD17B13
Nonalcoholic steatohepatitis (NASH)

ALN-PNP [4]
RNAi therapeutic targeting PNPLA3
NASH

DB-OTO
AAV-based gene therapy
Hearing loss in pediatrics (Phase 1/2)

FIANLIMAB
Antibody to LAG-3 | Solid tumors,
advanced hematologic malignancies

NTLA-2001 [3]
TTR gene knockout using CRISPR/Cas9
Transthyretin (ATTR) amyloidosis

ODRONEXTAMAB [5]
Bispecific antibody targeting CD20 and CD3
Certain B-cell malignancies

REGN4336
Bispecific antibody targeting PSMA and CD3
Prostate cancer

REGN5093
Bispecific antibody targeting
two distinct MET epitopes
MET-altered advanced non-small
cell lung cancer (NSCLC)

REGN5093-M114
Bispecific antibody-drug conjugate targeting
two distinct MET epitopes
MET overexpressing
advanced cancer

REGN5381/REGN9035
Agonist Antibody to NPR1/Reversal
Agent to REGN5381 | NPR1

LINVOSELTAMAB
Bispecific antibody targeting BCMA and CD3
Multiple myeloma

REGN5459
Bispecific antibody targeting BCMA and CD3
Transplant desensitization in patients
with chronic kidney disease

REGN5668
Bispecific antibody targeting MUC16 and CD28
Platinum-resistant ovarian cancer

REGN5678
Bispecific antibody targeting PSMA and CD28
Prostate cancer

REGN6569
Antibody to GITR | Solid tumors

REGN7075
Bispecific antibody targeting EGFR and CD28
Solid tumors

REGN7257
Antibody to IL2Rg | Aplastic anemia

REGN7508
Antibody to Factor XI | Thrombosis

REGN7999
Antibody to TMPRSS6
Transfusion dependent iron overload

REGN5837
Bispecific antibody targeting CD22 and CD28
B-NHL

Next Generation Covid Antibody
Antibody to SARS-CoV-2 Variants
SARS-CoV-2 Variants

REGN7544
Antagonist antibody to NPR1
Healthy volunteers

PHASE 2

ALN-HSD
RNAi therapeutic targeting HSD17B13 | NASH

CEMIPLIMAB
Antibody to PD-1 | Neoadjuvant cutaneous squamous
cell carcinoma (CSCC); First-line non-small cell lung
cancer (NSCLC), BNT116 combination

DUPILUMAB [1]
Antibody to IL-4R alpha subunit | Ulcerative colitis;
Eosinophilic gastroenteritis (Phase 2/3)

ODRONEXTAMAB [5]
Bispecific antibody targeting CD20 and CD3
B-cell non-Hodgkin lymphoma (B-NHL) (pivotal study)

FIANLIMAB
Antibody to LAG-3
First-line advanced NSCLC (Phase 2/3) (pivotal study)

MIBAVADEMAB
Agonist antibody to leptin receptor (LEPR)
Generalized lipodystrophy, partial lipodystrophy

REGN5381/REGN9035
Agonist antibody to NPR1/reversal agent to REGN5381 | Heart failure

LINVOSELTAMAB
Bispecific antibody targeting BCMA and CD3
Multiple myeloma (pivotal study)

SARILUMAB [1]
Antibody to IL-6R
Polyarticular-course juvenile idiopathic arthritis (pcJIA) (pivotal study),
systemic juvenile idiopathic arthritis (sJIA) (pivotal study)

VIDUTOLIMOD
Immune activator targeting TLR9 | Solid tumors

UBAMATAMAB
Bispecific antibody targeting MUC16 and CD3
Platinum-resistant ovarian cancer

REGN9933
Antibody to Factor XI
Thrombosis

PHASE 3

AFLIBERCEPT 8 MG
VEGF | Reinal vein occlusion (RVO)

ALIROCUMAB
Antibody to PCSK9 | HeFH in pediatrics
and adolescents

CEMIPLIMAB
Antibody to PD-1 | Adjuvant CSCC

DUPILUMAB [1]
IL-4R Alpha Subunit Antibody
EoE in pediatrics; chronic obstructive
pulmonary disease (COPD); bullous
pemphigoid; chronic spontaneous urticaria
(CSU); chronic pruritis of unknown origin

FIANLIMAB
Antibody to LAG-3
First-line metastatic melanoma;
First-line adjuvant melanoma

ITEPEKIMAB [1]
IL-33 Antibody | COPD

POZELIMAB
C5 | Myasthenia gravis,
cemdisiran combination; paroxysmal
nocturnal hemoglobinuria (PNH),
cemdisiran combination

REGN5713-5714-5715
Multi-antibody therapy to Bet v 1
Birch allergy

GARETOSMAB
Antibody to Activin A
Fibrodysplasia ossificans
progressiva (FOP)

LINVOSELTAMAB
BCMA and CD3 | Multiple myeloma

ODRONEXTAMAB [5]
CD20 and CD3 | Follicular lymphoma (FL);
Diffuse large B-cell lymphoma (DLBCL)

In collaboration with: [1] Sanofi | [2] Bayer | [3] Intellia | [4] Alnylam | [5] Zai Lab

- 🟩 Ophthalmology
- ⬜ Infectious Diseases
- 🟦 Immunology & Inflammatory Diseases
- 🟦 Oncology
- 🟥 Cardiovascular/Metabolic Diseases
- 🟥 Hematology
- 🟨 General Medicine
- 🟦 Rare Diseases
- 🟦 Neurology

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases.
The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Leaders in Technology

Fully human monoclonal antibodies
Regeneron has developed a suite of patented technologies (*VelociSuite*®), including *VelociGene*®, *VelocImmune*® and *VelociMab*®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Fusion proteins
Our novel and patented "Trap" fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

Regeneron Genetics Center®
A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Disability:IN & American Association of People with Disabilities:
Best Place to Work for Disability Inclusion, 2023
Civic 50: Most Community-Minded Companies in the Nation, 2023
Newsweek: America's Most Responsible Companies, 2023
Biospace: Best Place to Work, 2023
Glassdoor: Best Places to Work, 2023
Newsweek: America's Greatest Workplaces for Diversity, 2023
Prix Galien USA Award: Best Biotechnology Product (Inmazeb), 2022

Dow Jones Sustainability World Index, 2022
Dow Jones Sustainability North America Index, 2022
Science: Top Employer 2022
IDEA Pharma: Pharmaceutical Innovation Index, 2022
Forbes: JUST Companies, 2022
Fortune's Best Workplaces in New York, 2022
Civic 50: Most Community-Minded Companies in the Nation, 2022
Forbes: Best Employer – New York State, 2022

To learn more about us, please visit:
REGENERON.COM 🔗 REGENERON